Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
Francesco Salton, Paola Confalonieri, Stefano Centanni, Michele Mondoni, Nicola Petrosillo, Paolo Bonfanti, Giuseppe Lapadula, Donato Lacedonia, Antonio Voza, Nicoletta Carpenè, Marcella Montico, Nicolò Reccardini, Gianfranco Umberto Meduri, Barbara Ruaro, Marco Confalonieri
Source: Eur Respir J, 61 (4) 2201514; 10.1183/13993003.01514-2022
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Francesco Salton, Paola Confalonieri, Stefano Centanni, Michele Mondoni, Nicola Petrosillo, Paolo Bonfanti, Giuseppe Lapadula, Donato Lacedonia, Antonio Voza, Nicoletta Carpenè, Marcella Montico, Nicolò Reccardini, Gianfranco Umberto Meduri, Barbara Ruaro, Marco Confalonieri. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). Eur Respir J, 61 (4) 2201514; 10.1183/13993003.01514-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
|
|